Biocure Technology
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1055 W Hastings St Ste 300, Vancouver, B...Phone Number
(713) 360-2100Website
www.biocuretech.comRevenue
<$5 MillionStock Symbol
BICTFIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Biocure Technology
Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre- clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, and a hair growth production product.Explore more
Biocure Technology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biocure Technology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Biocure Technology had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Biocure Technology launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Biocure Technology recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Biocure Technology
Biocure Technology, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Biocure Technology has new funding data
Check if Biocure Technology has recently received funding, and reach out quickly before it becomes old news!
Check out if Biocure Technology is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Biocure Technology
Compare insights from companies similar to Biocure Technology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biocure Technology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biocure Technology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biocure Technology.
Biocure Technology News & Media
Biocure Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2022) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. BPK is currently under way to develop ROR1 CAR-T for a chronic leukemia treatment and Innovative CAR-T which can treat lung and ovarian cancer. All new CAR-T products under development are a bi-specific (dual antibody binding) CAR-T...Biocure Corporate Update and Financing
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. The Company continues to build financial value within Cancer Treatment through two ways; Development of it's own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies inBiocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia ("CLL") and Solid Tumor Cancers and Intent to Apply for Patents
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH) ("BioCure" or the "Company") is pleased to provide the following corporate update;BiocurePharm Corp. ("BPK"), a subsidiary of the Company is excited to announce its focus on the development of its own CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers. BPK is using an innovative concept of ROR1 CAR T-cell therapy combined with a double...BioCure Technology Inc. Lists on the Frankfurt Stock Exchange and Completion of Issuer Sponsored Research Report
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2021) - BioCure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (FSE: 1WH ) (CURE or the Company) - BioCure Technology Inc. ("BioCure" or the "Company") is pleased to announce listing on the Frankfurt Stock Exchange as of August 2, 2021 and the completion of an issuer sponsored research report by Pitt Street Research.BioCure Technology Inc. is pleased to announce that the company will begin trading on the Frankfurt Stock...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Biocure Technology
Sign Up For FreeTo access detailed company insights
Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre- clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim and Ranibizumab as well as CAR-T Cell Ther... Read More
